VolitionRX Ltd (NYSEAMERICAN:VNRX) Director Martin Charles Faulkes sold 65,000 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $3.21, for a total value of $208,650.00. Following the sale, the director now owns 1,505,943 shares in the company, valued at approximately $4,834,077.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
NYSEAMERICAN VNRX opened at $3.16 on Friday. VolitionRX Ltd has a one year low of $2.22 and a one year high of $6.84.
VolitionRX (NYSEAMERICAN:VNRX) last announced its earnings results on Thursday, August 13th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01. The firm had revenue of $0.01 million during the quarter.
Several hedge funds have recently bought and sold shares of VNRX. UBS Group AG lifted its position in shares of VolitionRX by 196.5% during the 2nd quarter. UBS Group AG now owns 13,338 shares of the medical research company’s stock valued at $51,000 after buying an additional 8,839 shares in the last quarter. American International Group Inc. bought a new position in shares of VolitionRX during the second quarter worth $56,000. New York State Common Retirement Fund purchased a new position in VolitionRX during the second quarter valued at $95,000. Jane Street Group LLC purchased a new position in VolitionRX during the first quarter valued at $96,000. Finally, Advisor Group Holdings Inc. purchased a new position in VolitionRX during the first quarter valued at $176,000.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
Recommended Story: Return on Equity (ROE)
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.